Share Email Print

Proceedings Paper

Design and development of receptor-avid peptide conjugates for in-vivo targeting of cancer
Author(s): Wynn A. Volkert; Timothy J. Hoffman
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Radiometallated peptides that exhibit high specificity for cognate receptors over expressed on cancer cells offer important potential as site-directed diagnostic and therapeutic radiopharmaceutical. The formation of effective radioactive drugs for specific in vivo targeting of cancerous tumors is being facilitated by the integration of novel chelation strategies and receptor-avid derivatives. Significant efforts are being made to design Technetium-99m labeled for diagnostic imaging of cancerous tumors for use in conjunction with Single Photon Emission Tomography instrumentation in nuclear medicine. Receptor avid radiopharmaceutical are also being developed that utilize other radionuclides for imaging and therapeutic applications. Despite the technological challenges that must be overcome, radiolabeled receptor avid peptide conjugates are providing promising site-directed targeting agents for the assessment and treatment of cancerous tumors in humans.

Paper Details

Date Published: 2 July 1999
PDF: 13 pages
Proc. SPIE 3600, Biomedical Imaging: Reporters, Dyes, and Instrumentation, (2 July 1999); doi: 10.1117/12.351016
Show Author Affiliations
Wynn A. Volkert, H. S. Truman Veterans Hospital and Univ. of Missouri/Columbia (United States)
Timothy J. Hoffman, H. S. Truman Veterans Hospital and Univ. of Missouri/Columbia (United States)

Published in SPIE Proceedings Vol. 3600:
Biomedical Imaging: Reporters, Dyes, and Instrumentation
Eva Marie Sevick-Muraca; Darryl J. Bornhop; Christopher H. Contag; Eva Marie Sevick-Muraca, Editor(s)

© SPIE. Terms of Use
Back to Top